Table of Contents

Orchid Pharma Ltd

Updated on November 14, 2024

Stock/Share Code - ORCHIDPHAR

Orchid Pharma formerly Orchid Chemicals & Pharmaceuticals Limited, is involved in the development, manufacture and marketing of various bulk actives, formulations and nutraceuticals.

Below is the details of ORCHIDPHAR Orchid Pharma Ltd

Market Cap	₹48.49 Cr.
Current Price	₹5.45
52 Week High / Low Price	/
Face Value	₹10
Stock P/E
Book Value	₹118.72
Dividend Yield	0.00 %
ROCE	-7.23 %
ROE	-99.49 %
Sales Growth (3yrs)	-12.53 %
Sector	Pharmaceuticals
Industry	Pharmaceuticals - Indian - Bulk Drugs
Listed on	BSE AND NSE
Company Website	Company Website

Pros: Company has reduced debt. Stock is trading at 0.05 times its book value Debtor days have improved from 72.71 to 47.93 days.

Cons: Company has low interest coverage ratio. The company has delivered a poor growth of -21.87% over past five years. Promoter holding is low: 26.68% Contingent liabilities of Rs.142.90 Cr. Company might be capitalizing the interest cost Promoters have pledged 99.96% of their holding.

Orchid Pharma Ltd Peer Comparison in Pharmaceuticals

S.No.	Name	P/E	Mar Cap Rs.Cr.	Div Yld %	NP Qtr Rs.Cr.	Qtr Profit Var %	Qtr Sales Var %	Sales Qtr Rs.Cr.	ROCE %
1.	Divi's Lab.	51.94	₹82,900.53 Cr.	0.51	₹492.06 Cr.	80.61	48.81	1730.47	25.19
2.		₹42,032.3 Cr.	0.65	₹106.9 Cr.	-64.73	-9.02	3527.86	9.23
3.	Jubilant Life	13.50	₹12,477.17 Cr.	0.64	₹260.49 Cr.	248.25	0.24	2391.41	15.46
4.	Granules India	22.60	₹7,765.53 Cr.	0.32	₹111.45 Cr.	33.89	23.57	735.60	17.15
5.	Aarti Drugs	31.46	₹6,319.31 Cr.	0.07	₹85.45 Cr.	280.62	34.34	544.67	20.87
6.	Shilpa Medicare	23.66	₹4,289.13 Cr.	0.21	₹86.31 Cr.	159.66	38.43	222.86	12.62
7.	Sequent Scien.	40.58	₹3,221.37 Cr.	0.15	₹20.92 Cr.	82.55	11.60	310.27	12.29
8.	Orchid Pharma		₹48.49 Cr.	0.00	-₹54.31 Cr.	-57.10	-32.06	110.11	-7.23

Ready to Invest?
Talk to our investment specialist

Orchid Pharma Ltd Fundamentals

Quarterly Results

Quarterly reports are issued by companies every three months. Most companies have a financial year-end of Mar. 31 and quarters that end on June 30, Sept. 30, Dec. 31 and March 31.

Standalone Figures in Rs. Crores

	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020
Sales -	135	209	144	156	131	142	148	162	136	131	129	110
YOY Sales Growth %	-25.80%	11.51%	-19.86%	-23.96%	-3.08%	-31.94%	2.92%	4.03%	3.92%	-8.06%	-13.38%	-32.06%
Expenses -	167	186	131	148	145	146	136	170	145	129	138	138
Material Cost %	63%	54%	44%	44%	52%	42%	48%	49%	49%	42%	43%	58%
Employee Cost %	16%	9%	14%	14%	15%	14%	13%	13%	15%	16%	17%	17%
Operating Profit	-32	24	14	8	-14	-3	12	-8	-9	2	-9	-28
OPM %	-24%	11%	9%	5%	-11%	-2%	8%	-5%	-7%	1%	-7%	-25%
Other Income	5	5	8	1	15	13	2	26	5	7	7	6
Interest	71	75	76	79	14	0	0	0	0	2	1	1
Depreciation	34	34	33	33	33	33	33	31	31	32	32	31
Profit before tax	-131	-81	-88	-103	-46	-23	-18	-13	-36	-25	-35	-54
Tax %	13%	13%	12%	10%	-0%	0%	0%	0%	0%	0%	0%	0%
Net Profit	-114	-70	-77	-92	-46	-23	-18	-13	-36	-25	-35	-54
EPS in Rs	-12.87	-7.91	-8.68	-10.38	-5.17	-2.60	-2.08	-1.51	-4.00	-2.83	-3.91	-13.31
	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes

Profit & Loss

The profit and loss (P&L) statement is a financial statement that summarizes the revenues, costs and expenses incurred during a specified period, usually a fiscal quarter or year. The P&L statement is synonymous with the income statement. These records provide information about a company's ability or inability to generate profit" by increasing revenue, reducing costs or both. Some refer to the P&L statement as a statement of profit and loss, income statement, statement of operations, statement of financial results or income, earnings statement or expense statement.

Standalone Figures in Rs. Crores

	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Sep 2013	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
Sales -	1,239	1,191	1,250	1,663	1,736	1,907	1,736	879	755	644	584	505
Sales Growth %	35.71%	-3.83%	4.90%	33.09%	4.39%	9.81%	-8.94%	-49.35%	-14.10%	-14.72%	-9.40%	-13.40%
Expenses -	894	1,031	1,423	1,315	1,455	1,833	1,345	705	740	622	766	550
Material Cost %	35.08%	42.83%	62.03%	47.37%	45.26%	50.26%	45.00%	47.68%	48.65%	51.36%	47.66%	47.53%
Manufacturing Cost %	11.71%	11.70%	10.98%	11.24%	12.12%	13.64%	12.89%	13.38%	13.76%	15.29%	15.52%	0.00%
Employee Cost %	8.65%	10.61%	13.00%	9.05%	9.29%	12.89%	10.84%	9.49%	9.99%	12.91%	13.64%	16.12%
Other Cost %	16.72%	21.41%	27.81%	11.39%	17.12%	19.34%	8.74%	9.65%	25.58%	16.99%	54.41%	45.11%
Operating Profit	345	160	-173	349	282	74	391	174	15	22	-182	-44
OPM %	28%	13%	-14%	21%	16%	4%	23%	20%	2%	3%	-31%	-9%
Other Income	73	88	1,025	69	126	147	84	-28	-59	20	218	24
Interest	82	155	241	116	179	520	537	294	347	310	7	4
Depreciation	98	130	151	128	149	244	321	143	146	133	130	126
Profit before tax	239	-37	460	174	80	-544	-383	-292	-537	-401	-101	-150
Tax %	23%	-42%	28%	8%	-29%	2%	50%	6%	9%	12%	0%	0%
Net Profit	185	-52	331	159	103	-530	-191	-274	-489	-355	-101	-150
EPS in Rs	27.27	0.00	44.94	22.05	14.15	0.00	0.00	0.00	0.00	0.00	0.00	-36.71
Dividend Payout %	11%	-14%	21%	13%	20%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth

10 Years:: -8.66%
5 Years:: -21.87%
3 Years:: -12.53%
TTM:: -13.40%

Compounded Profit Growth

10 Years:: 5.63%
5 Years:: 8.56%
3 Years:: 17.63%
TTM:: -18.93%

Return on Equity

10 Years:: -29.77%
5 Years:: -36.98%
3 Years:: -33.22%
1 Year:: 0.00%

Balance Sheet

A balance sheet is a financial statement that reports a company's assets, liabilities and shareholders' equity at a specific point in time, and provides a basis for computing rates of return and evaluating its capital structure. It is a financial statement that provides a snapshot of what a company owns and owes, as well as the amount invested by shareholders. It is used alongside other important financial statements such as the income statement and statement of cash flows in conducting fundamental analysis or calculating financial ratios.

Standalone Figures in Rs. Crores

	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Sep 2013	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
Share Capital -	66	70	70	70	70	70	85	89	89	89	89	41
Equity Capital	65.85	70.44	70.44	70.44	70.44	70.45	85.26	88.96	88.96	88.96	88.96	40.82
Reserves	622	600	909	1,064	1,076	418	354	82	-432	-763	-844	1,015
Borrowings	1,953	2,597	1,630	2,069	1,996	3,204	3,211	3,214	3,106	3,202	3,230	501
Other Liabilities -	828	955	1,179	686	756	1,031	506	577	595	683	518	154
Trade Payables	219	309	283	262	404	562	296	353	412	327	270	62
Advance from Customers	0	0	0	11	69	51	12	21	20	3	11
Other liability items	608	646	896	413	284	418	199	203	163	354	238	92
Total Liabilities	3,469	4,222	3,788	3,888	3,899	4,723	4,156	3,963	3,358	3,211	2,993	1,712
Fixed Assets -	1,414	1,866	1,463	1,596	1,931	2,483	1,697	1,540	1,402	1,291	1,161	1,049
Gross Block	1,961	2,536	2,184	2,453	2,919	3,660	2,890	2,893	1,540	1,425	1,425
Accumulated Depreciation	547	669	721	857	987	1,177	1,193	1,353	139	133	263
CWIP	616	546	468	330	350	360	282	280	288	272	278	78
Investments	114	122	124	130	149	124	125	125	125	125	0	0
Other Assets -	1,325	1,687	1,733	1,832	1,468	1,756	2,053	2,017	1,543	1,523	1,553	584
Inventories	633	744	403	580	624	500	242	210	197	185	167	155
Trade receivables	523	659	716	481	91	184	290	375	208	145	141	66
Cash Equivalents	23	42	325	193	170	22	390	313	256	301	324	174
Loans n Advances	220	330	289	273	424	500	425	425	42	60	82	1
Other asset items	-73	-87	0	305	160	550	706	693	840	832	840	187
Total Assets	3,469	4,222	3,788	3,888	3,899	4,723	4,156	3,963	3,358	3,211	2,993	1,712

Cash Flows

Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business. At the most fundamental level, a company’s ability to create value for shareholders is determined by its ability to generate positive cash flows, or more specifically, maximize long-term free cash flow.

Standalone Figures in Rs. Crores

	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Sep 2013	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
Cash from Operating Activity -	216	35	-40	312	764	175	-370	211	402	6	15	80
Profit from operations	397.77	182.26	-65.32	422.83	345.29	165.58	761.75	204.04	-42.80	48.30	134.14	24.75
Receivables	-189.29	-66.31	-204.47	111.93	373.55	-194.30	-632.92	-78.31	127.32	63.00	-4.43	38.14
Inventory	-30.92	-110.50	341.16	-177.73	-43.33	123.52	257.80	31.93	12.89	12.51	17.83	12.32
Payables	71.01	32.09	-45.76	16.25	117.19	80.11	-293.45	53.63	42.85	-93.56	-58.26	-1.42
Other WC items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	266.49	-17.63	-69.82	-3.81
Working capital changes	-149.20	-144.72	90.93	-49.55	447.41	9.33	-668.57	7.26	449.56	-35.68	-114.68	45.22
Direct taxes	-32.19	-2.74	-65.89	-61.16	-28.80	0.00	-47.03	0.00	-5.16	-7.04	-4.28	0.00
Other operating items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.42
Exceptional CF items	0.00	0.00	0.00	0.00	0.00	0.00	-415.87	0.00	0.00	0.00	0.00	0.00
Cash from Investing Activity -	-554	-466	1,413	-362	-309	-998	1,334	-1	-176	-28	45	167
Fixed assets purchased	-553	-462	-223	-377	-292	-1,152	-83	-1	-9	-6	-7	-4
Fixed assets sold	1	1	1,637	19	1	77	1	0	0	0	0	0
Investments purchased	0	0	0	0	-18	0	0	0	-0	0	0	0
Investments sold	0	0	0	0	0	77	0	0	0	0	0	0
Interest received	0	0	0	0	0	0	0	0	15	12	15	24
Dividends received	0	3	0	3	0	0	0	0	0	0	0	0
Invest in subsidiaries	-1	-9	-1	-7	0	0	0	0	0	0	0	0
Other investing items	0	0	0	0	0	0	1,416	0	-182	-34	37	147
Cash from Financing Activity -	248	429	-1,071	-73	-478	676	-597	-287	-465	33	-0	-250
Proceeds from shares	1	110	0	0	0	0	74	18	0	0	0	40
Proceeds from borrowings	723	990	731	627	916	458	66	13	0	39	0	754
Repayment of borrowings	-331	-394	-1,413	-336	-301	-173	-484	-53	-103	-1	0	-1,044
Interest paid fin	-121	-195	-288	-167	-245	-351	-150	-265	-362	-4	-0	-0
Dividends paid	-23	-25	-8	-82	-25	0	0	0	0	0	0	0
Financial liabilities	-0	-0	-1	-1	0	0	0	0	0	0	0	0
Other financing items	0	-56	-93	-114	-824	743	-102	0	0	0	0	0
Net Cash Flow	-89	-3	302	-123	-24	-147	367	-76	-239	11	60	-3

Ready to Invest?
Talk to our investment specialist

Ratios

	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Sep 2013	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
ROCE %	13%	4%	-11%	9%	8%	-2%	1%	2%	-3%	-3%	-5%	-7%
Debtor Days	154	202	209	106	19	35	61	156	101	82	88	48
Inventory Turnover	0.82	0.85	1.47	1.75	1.45	1.92	2.38	2.10	2.07	2.00	1.86	1.49

Announcements & News

Recent Announcements

Credit Ratings

Orchid Pharma Limited 3 Sep 2019 from care
Orchid Pharma Limited 6 Apr 2018 from care
Orchid Pharma Limited 17 Apr 2017 from care

Annual Reports

How to Invest in Mutual Funds SIP Online?

Open Free Investment Account for Lifetime at Fincash.com.
Complete your Registration and KYC Process
Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest! Get Started
Invest in Mutual Funds which invests in Orchid Pharma Ltd & Get More Returns than Bank Deposit

Disclaimer:
All efforts have been made to ensure the information provided here is accurate as per time to time filling by company to exchanges. However, no guarantees are made regarding correctness of data. Investors are advised to validate/check information with exchanges or companies website before making any investment decisions.

Shepard Technologies Pvt. Ltd : 1808, Solus, Hiranandani Estate, Thane, Maharashtra - 400607

AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153

Mutual fund investments are subject to market risks. Please read the scheme information and other related documents carefully before investing. Past performance is not indicative of future returns. Please consider your specific investment requirements before choosing a fund, or designing a portfolio that suits your needs.

Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.